Skip to main content
. 2021 Nov 1;6:374. doi: 10.1038/s41392-021-00773-3

Fig. 2.

Fig. 2

Kaplan–Meier curves comparing the PFS (a) and OS (b) of patients with advanced EGFR–mutant non-small-cell lung cancer who had concomitant TP53 mutations as compared to patients who had wild-type TP53. Patients who experienced ctDNA clearance at first follow-up had significantly longer survival outcomes. Kaplan–Meier curves comparing the PFS (c) and OS (d) of patients with EGFR–mutant non-small-cell lung cancer who experienced ctDNA clearance at first follow-up compared with patients who had detectable mutations